Curi RMB Capital’s Neurocrine Biosciences NBIX Stock Holding History

Curi RMB Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$438K	Sell	3,327 -907	-21%	-$120K	0.01%	638
2025 Q4	$601K	Buy	+4,234	New	+$613K	0.01%	562
2019 Q1	–	Sell	-22,416	Closed	-$1.6M	–	886
2018 Q4	$1.6M	Sell	22,416 -18	-0.1%	-$1.73K	0.04%	400
2018 Q3	$2.76M	Sell	22,434 -3,631	-14%	-$412K	0.07%	313
2018 Q2	$2.56M	Sell	26,065 -12,868	-33%	-$1.15M	0.06%	329
2018 Q1	$3.23M	Sell	38,933 -18,344	-32%	-$1.55M	0.08%	307
2017 Q4	$4.44M	Sell	57,277 -5,775	-9%	-$394K	0.12%	244
2017 Q3	$3.86M	Buy	63,052 +13,590	+27%	+$717K	0.1%	282
2017 Q2	$2.27M	Buy	+49,462	New	+$2.4M	0.07%	352

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Curi RMB Capital's NBIX Position: Q1 2026 in Review

Curi RMB Capital reduced its Neurocrine Biosciences (NBIX) stake by 21% in Q1 2026, selling an estimated $120K and leaving 3,327 shares worth $438K. The position accounts for 0.01% of the portfolio, ranked #638.

Curi RMB Capital first reported a position in NBIX in Q2 2017 and has held it in 9 quarters since. The position peaked at $4.44M in Q4 2017. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Curi RMB Capital held 3,327 shares of Neurocrine Biosciences worth $438K as of Q1 2026.
Curi RMB Capital sold 907 Neurocrine Biosciences shares in Q1 2026, an estimated $120K.
Neurocrine Biosciences made up 0.01% of Curi RMB Capital's portfolio in Q1 2026, its #638 holding.
Curi RMB Capital first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 9 quarters since.
Curi RMB Capital's Neurocrine Biosciences position peaked at $4.44M in Q4 2017.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Curi RMB Capital's 13F filing for Q1 2026, filed 15 May 2026.